EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study

Haifa Kathrin Al-Ali, Paola Guglielmelli, Claire N Harrison, Ruben A Mesa, J E Hamer-Maansson, Evan Braunstein, Vikas Gupta

Acta Haematologica · 2025

DOI: 10.1159/000546585 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Haematologica, 2025. Verfasst von Haifa Kathrin Al-Ali und 6 weiteren Autor:innen. Beteiligte Einrichtung: Krukenberg Cancer Center, University Hospital Halle, Halle (Saale), Germany, haifa.al-ali@uk-halle.de. Hauptthemen laut MEDLINE: Pyrazoles, Primary Myelofibrosis, Anemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Anemia can influence decisions regarding initiation, dosing, and discontinuation of Janus kinase inhibitor therapy for myelofibrosis. We evaluated the impact of new-onset or worsening anemia following ruxolitinib initiation on spleen response, symptom severity, and overall survival in patients with myelofibrosis.

Methods

This post hoc analysis used data from all patients enrolled in the phase 3b JUMP trial. Outcomes were stratified by presence or absence of new-onset or worsening anemia following ruxolitinib initiation, defined as hemoglobin decrease ≥15 g/L from baseline and hemoglobin

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesPrimary MyelofibrosisAnemiaHumansNitrilesPyrimidinesFemaleMaleAgedSpleenTreatment OutcomeMiddle Aged

Stichwörter der Autor:innen

AnemiaMyelofibrosisMyeloproliferative neoplasmRuxolitinibSplenomegalySurvival

Substanzen

ruxolitinibNitrilesPyrimidinesPyrazoles

Autor:innen und Institutionen

  • Krukenberg Cancer Center, University Hospital Halle, Halle (Saale), Germany, haifa.al-ali@uk-halle.de.
  • Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera-Universitaria Careggi, University of Florence, Florence, Italy.
  • Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Incyte Corporation, Wilmington, Delaware, USA.
  • Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Zitieren

APA

Al-Ali, H. K., Guglielmelli, P., Harrison, C. N., Mesa, R. A., Hamer-Maansson, J. E., Braunstein, E., & Gupta, V. (2025). Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study. Acta Haematologica. https://doi.org/10.1159/000546585

Vancouver

Al-Ali HK, Guglielmelli P, Harrison CN, Mesa RA, Hamer-Maansson JE, Braunstein E, et al. Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study. Acta Haematologica. 2025. doi:10.1159/000546585

BibTeX
@article{AlAli2025,
  author = {Al-Ali, Haifa Kathrin and Guglielmelli, Paola and Harrison, Claire N and Mesa, Ruben A and Hamer-Maansson, J E and Braunstein, Evan and Gupta, Vikas},
  title = {Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study},
  journal = {Acta Haematologica},
  year = {2025},
  doi = {10.1159/000546585}
}
Kostenlos starten →